華泰證券(06886.HK)完成發行30億元公司債券
格隆匯5月21日丨華泰證券(06886.HK)公佈,經中國證券監督管理委員會"證監許可[2020]406號"文核准,華泰證券獲准向合格投資者公開發行不超過200億元人民幣公司債券,華泰證券2020年面向合格投資者公開發行公司債券(第三期)發行規模為不超過50億元(含50億元)。該期債券發行價格為每張人民幣100元,全部採用網下面向合格投資者詢價配售的方式發行。
該期公司債券發行工作已於2020年5月21日結束,最終發行規模為人民幣30億元,票面利率為3.20%。其中,發行人的關聯方江蘇省國際信託有限責任公司參與了該期債券的認購,最終獲配金額為2,000萬元,佔該期債券發行規模的0.67%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.